JP2020530294A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530294A5
JP2020530294A5 JP2020506981A JP2020506981A JP2020530294A5 JP 2020530294 A5 JP2020530294 A5 JP 2020530294A5 JP 2020506981 A JP2020506981 A JP 2020506981A JP 2020506981 A JP2020506981 A JP 2020506981A JP 2020530294 A5 JP2020530294 A5 JP 2020530294A5
Authority
JP
Japan
Prior art keywords
cells
naive
composition
cell
stimulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020506981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530294A (ja
JP7824728B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/046151 external-priority patent/WO2019032929A1/en
Publication of JP2020530294A publication Critical patent/JP2020530294A/ja
Publication of JP2020530294A5 publication Critical patent/JP2020530294A5/ja
Priority to JP2023015156A priority Critical patent/JP2023055888A/ja
Priority to JP2024223646A priority patent/JP2025031794A/ja
Application granted granted Critical
Publication of JP7824728B2 publication Critical patent/JP7824728B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020506981A 2017-08-09 2018-08-09 遺伝子操作された細胞を調製するための方法および組成物 Active JP7824728B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023015156A JP2023055888A (ja) 2017-08-09 2023-02-03 遺伝子操作された細胞を調製するための方法および組成物
JP2024223646A JP2025031794A (ja) 2017-08-09 2024-12-19 遺伝子操作された細胞を調製するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762543359P 2017-08-09 2017-08-09
US62/543,359 2017-08-09
PCT/US2018/046151 WO2019032929A1 (en) 2017-08-09 2018-08-09 METHODS AND COMPOSITIONS FOR PREPARING GENETICALLY MODIFIED CELLS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023015156A Division JP2023055888A (ja) 2017-08-09 2023-02-03 遺伝子操作された細胞を調製するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2020530294A JP2020530294A (ja) 2020-10-22
JP2020530294A5 true JP2020530294A5 (https=) 2021-09-16
JP7824728B2 JP7824728B2 (ja) 2026-03-05

Family

ID=63405422

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020506981A Active JP7824728B2 (ja) 2017-08-09 2018-08-09 遺伝子操作された細胞を調製するための方法および組成物
JP2023015156A Pending JP2023055888A (ja) 2017-08-09 2023-02-03 遺伝子操作された細胞を調製するための方法および組成物
JP2024223646A Pending JP2025031794A (ja) 2017-08-09 2024-12-19 遺伝子操作された細胞を調製するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023015156A Pending JP2023055888A (ja) 2017-08-09 2023-02-03 遺伝子操作された細胞を調製するための方法および組成物
JP2024223646A Pending JP2025031794A (ja) 2017-08-09 2024-12-19 遺伝子操作された細胞を調製するための方法および組成物

Country Status (12)

Country Link
US (2) US20200239910A1 (https=)
EP (2) EP3664835B1 (https=)
JP (3) JP7824728B2 (https=)
KR (2) KR20250096881A (https=)
CN (2) CN111263641B (https=)
AU (2) AU2018313952B2 (https=)
BR (1) BR112020001601A2 (https=)
CA (1) CA3070575A1 (https=)
ES (1) ES2992909T3 (https=)
MA (1) MA49981A (https=)
MX (1) MX2020001491A (https=)
WO (1) WO2019032929A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102550778B1 (ko) 2017-05-26 2023-07-03 에이비비트로 엘엘씨 고-처리량 폴리뉴클레오타이드 라이브러리 시퀀싱 및 전사체 분석
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
KR20250016455A (ko) 2017-08-09 2025-02-03 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
US12258580B2 (en) 2017-11-01 2025-03-25 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
US12161670B2 (en) * 2017-12-08 2024-12-10 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
MX2020005907A (es) 2017-12-08 2020-10-19 Juno Therapeutics Inc Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
US12516099B2 (en) * 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
SG11202104355SA (en) 2018-10-31 2021-05-28 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
AU2019372673A1 (en) 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
CA3142108A1 (en) 2019-05-28 2020-12-03 Miltenyi Biotec B.V. & Co. KG Method for generation of genetically modified t cells
JP2022554348A (ja) 2019-11-05 2022-12-28 ジュノー セラピューティクス インコーポレイテッド 治療用t細胞組成物の属性を決定する方法
JP2023512209A (ja) * 2020-01-28 2023-03-24 ジュノー セラピューティクス インコーポレイテッド T細胞形質導入のための方法
IL295381B1 (en) * 2020-02-12 2026-04-01 Juno Therapeutics Inc BCMA-directed chimeric T-cell antigen receptor compounds and methods and uses thereof
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
KR20230152783A (ko) 2020-07-07 2023-11-03 칸큐어 엘엘씨 Mic 항체 및 결합제 및 이의 사용 방법
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
CN119506185A (zh) * 2023-08-22 2025-02-25 深圳赛桥生物创新技术有限公司 细胞样本处理方法、装置、系统和介质
WO2025097034A1 (en) * 2023-11-03 2025-05-08 Kyverna Therapeutics, Inc. Methods for manufacture of engineered t cells from whole blood samples

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
TW200502391A (en) 2003-05-08 2005-01-16 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
CA2679400A1 (en) * 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
CA2814047C (en) 2010-10-08 2017-11-14 President And Fellows Of Harvard College High-throughput immune sequencing
GB2497912B (en) 2010-10-08 2014-06-04 Harvard College High-throughput single cell barcoding
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) * 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
MX2013011363A (es) 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
GB2525568B (en) 2013-03-15 2020-10-14 Abvitro Llc Single cell barcoding for antibody discovery
EP3783098A1 (en) * 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
CA2946312A1 (en) * 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
CN113604491A (zh) 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
EP3950944A1 (en) 2014-09-15 2022-02-09 AbVitro LLC High-throughput nucleotide library sequencing
BR112017011932A8 (pt) 2014-12-05 2022-11-08 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
SI3226897T1 (sl) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe
CN118271463A (zh) 2014-12-05 2024-07-02 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
MY191537A (en) 2014-12-05 2022-06-30 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
JP6961490B2 (ja) * 2015-04-08 2021-11-05 ノバルティス アーゲー Cd20療法、cd22療法、およびcd19キメラ抗原受容体(car)発現細胞との併用療法
WO2016166568A1 (en) * 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
AU2016253964B2 (en) 2015-04-27 2022-07-07 Abvitro Llc Methods of sequencing, determining, pairing, and validating therapeutic agents and disease specific antigens
MX2018003534A (es) 2015-09-25 2019-04-25 Abvitro Llc Proceso de alto rendimiento para identificacion de blanco de receptor de celula t de secuencias de receptor de celula t apareadas de manera natural.
MX2018004875A (es) 2015-10-22 2018-08-01 Juno Therapeutics Gmbh Metodos para cultivar celulas y kits y aparatos para ello.

Similar Documents

Publication Publication Date Title
JP2020530294A5 (https=)
JP2021505168A5 (https=)
Maeda et al. Regeneration of CD8αβ T cells from T-cell–derived iPSC imparts potent tumor antigen-specific cytotoxicity
CN111263641B (zh) 用于制备基因工程化细胞的方法和组合物
Gargett et al. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2
KR102229421B1 (ko) 항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법
Ptáčková et al. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21
JP2022512913A5 (https=)
JP2022185055A (ja) 組換え受容体を発現している細胞を増大させるための試薬
US11299552B2 (en) Eliminating MHC restriction from the T cell receptor as a strategy for immunotherapy
JP5934897B2 (ja) T細胞レセプターβ鎖遺伝子及びα鎖遺伝子
JP2021501604A5 (https=)
JP2021505615A5 (https=)
CN105473731A (zh) 自身癌抗原特异性cd8+t细胞的分离及增殖方法
JP2020527036A (ja) 癌免疫療法用mr1制限t細胞受容体
Matsuzaki et al. A rare population of tumor antigen-specific CD4+ CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells
JP2021536260A (ja) 抗原特異的car−t細胞を拡大増殖する方法、それに関連する組成物及び使用
CN111826353B (zh) 调节t细胞功能和反应的方法
Blaeschke et al. Human HLA-A* 02: 01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo
JP2022500038A (ja) 癌免疫療法用mr1制限t細胞受容体
Weinstein-Marom et al. Genetic modification of tumor-infiltrating lymphocytes via retroviral transduction
Hillerdal et al. Avidity characterization of genetically engineered T-cells with novel and established approaches
Hu et al. Application of adoptive cell therapy in malignant melanoma
KR20230022868A (ko) 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
CN112779223A (zh) 偶联嵌合抗原受体细胞及其用途